Thursday, February 25, 2021

Newcomer Covid-19 vaccine works in UK trials as world worries about scarce supplies

The trials suggest the vaccine is nearly 96% effective against the older coronavirus and nearly 86% effective against the new variants.

Other News

Tidak perlu surat polis rentas negeri hantar anak ke asrama

Ibu bapa hanya perlu menunjukkan surat yang dikeluarkan pihak sekolah semasa melalui sekatan jalan raya.

No police permit needed to cross borders for school

Parents only need to show letters issued by the schools at police roadblocks.

Kes baru Covid-19 jatuh bawah 2,000

12 lagi kematian dicatatkan.

New cases drop below 2,000 mark

12 more deaths reported.

MIC leader questions ‘fickle-minded’ Umno chiefs

MIC deputy president M Saravanan says the party will only decide based on discussions in Barisan Nasional.

American company Novavax said on Thursday that its vaccine appears to be 89% effective based on early findings from a British study.

It also seems to work – though not as well – against new mutated versions of the virus circulating in UK and South Africa, and now elsewhere, reports the Associated Press.

The announcement comes amid worry about whether a variety of vaccines being rolled out around the world will be strong enough to protect against new variants, and as countries desperately need to boost scarce supplies.

UK Health Secretary Matt Hancock told the BBC the NHS “stands ready” to roll the jab out if it is approved.

He said: “This is positive news and, if approved by the medicines regulator, the Novavax vaccine will be a significant boost to our vaccination programme and another weapon in our arsenal to beat this awful virus.”

Novavax said the trials suggest the vaccine is nearly 96% effective against the older coronavirus and nearly 86% effective against the new variants.

“Both those numbers are dramatic demonstrations of the ability of our vaccine to develop a very potent immune response,” Novavax CEO Stanley Erck said in a call with investors late on Thursday.

Novavax said it needs some additional data before it can seek British authorisation for the vaccine’s use, sometime in the next month or so.

A larger study in the US and Mexico has enrolled slightly over half of the needed 30,000 volunteers.

Meanwhile, Novavax is starting to develop a version of the vaccine that could more specifically target the mutations found in South Africa and the UK.

Vaccines against Covid-19 train the body to recognise the new coronavirus, mostly focusing on the spike protein that coats it.

The Novavax vaccine is called a recombinant protein vaccine. It uses genetic engineering to grow harmless copies of the coronavirus spike protein in insect cells. Scientists extract and purify the protein and then mix in an immune-boosting chemical.

Follow us on Telegram for the latest updates: https://t.me/malaysianow

Subscribe to our newsletter

To be updated with all the latest news and analyses.

Related Articles

New cases drop below 2,000 mark

12 more deaths reported.

Health ministry explains different needle colours for Covid jabs

Different colours signify different bore size in needles, health ministry says.

As vaccination begins, theories against jabs surface in the form of ‘medical research’

One such claim in a 'medical journal' warns that Pfizer's vaccine could lead to brain-related disease.

Kenya bans its runners from Tanzania marathon over Covid-19 fears

The Tanzanian government has been criticised for downplaying the seriousness of the pandemic and refusing to take tough measures against it.

Sweden scraps relaxed approach to pandemic on fears of third wave

The country has never imposed the type of lockdown seen elsewhere in Europe, and until now prioritised social distancing over the use of face masks.